Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 26, 2015 4:46 AM ET

Biotechnology

Company Overview of Palatin Technologies Inc.

Company Overview

Palatin Technologies, Inc., a biopharmaceutical company, develops peptide therapeutics for the treatment of diseases. The company’s clinical development product is Bremelanotide, a peptide melanocortin receptor agonist that has completed Phase 2B clinical trial for the treatment of female sexual dysfunction (FSD). Its drug development programs include Melanocortin receptor-1 agonist peptides for the treatment of inflammatory and dermatologic disease indications; Next Generation Melanocortin receptor-4 peptide agonists, which is in preclinical trials for the treatment of erectile dysfunction; and PL-3994, a natriuretic peptide receptor-A agonist that has completed Phase I clinical trial for t...

4B Cedar Brook Drive

Cranbury, NJ 08512

United States

Founded in 1986

Phone:

609-495-2200

Fax:

609-495-2201

Key Executives for Palatin Technologies Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 52
Total Annual Compensation: $450.0K
Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer and Secretary
Age: 57
Total Annual Compensation: $410.0K
Compensation as of Fiscal Year 2014.

Palatin Technologies Inc. Key Developments

Palatin Technologies Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2015

Palatin Technologies Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended March 31, 2015. For the quarter, the company's loss from operations was $8,722,391 compared to $3,363,738 a year ago. Loss before income taxes was $9,150,538 compared to $3,359,557 a year ago. Net loss was $9,150,538 compared to $1,512,911 a year ago. Basic and diluted net loss per common share was $0.07 compared to $0.01 a year ago. The increase in net loss for the quarter ended March 31, 2015 compared to the same period last fiscal year was attributable to the increase in research and development expenses related to Phase 3 reconnectstudy with bremelanotide for the treatment of FSD. For the nine months, the company's loss from operations was $5,505,865 compared to $11,466,826 a year ago. Loss before income taxes was $6,110,584 compared to $11,455,200 a year ago. Net loss was $5,579,076 compared to $9,608,554 a year ago. Basic and diluted net loss per common share was $0.05 compared to $0.09 a year ago. Contract revenues were $12,951,730.

Palatin Technologies Inc. to Report Q3, 2015 Results on May 13, 2015

Palatin Technologies Inc. announced that they will report Q3, 2015 results at 9:00 AM, Eastern Standard Time on May 13, 2015

Palatin Technologies Inc., Q3 2015 Earnings Call, May 13, 2015

Palatin Technologies Inc., Q3 2015 Earnings Call, May 13, 2015

Similar Private Companies By Industry

Company Name Region
Molecular Transfer, Inc. United States
Selventa, Inc. United States
Baxalta Inc. United States
Juniper Medical, Inc. United States
Tamir Biotechnology, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
December 24, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Palatin Technologies Inc., please visit www.palatin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.